Description
BLANKET PO FOR FY16 FOR THE DRUG GLASSIA, ALPHA 1-PROTEINASE INHIBITOR HUMAN, 1GM/50ML VIAL 1200 VIALS.
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2015-10-27+$276,000= $276,000
- Mod P000012016-04-05+$29,400= $305,400
- Mod P000022016-08-30-$88,400= $217,000
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2015-10-27 | +$276,000 | $276,000 | BLANKET PO FOR FY16 FOR THE DRUG GLASSIA, ALPHA 1-PROTEINASE INHIBITOR HUMAN, 1GM/50ML VIAL 1200 VIALS. |
| Mod P00001· FUNDING ONLY ACTION | 2016-04-05 | +$29,400 | $305,400 | BLANKET PO FOR FY16 FOR THE DRUG GLASSIA, ALPHA 1-PROTEINASE INHIBITOR HUMAN, 1GM/50ML VIAL 1200 VIALS. |
| Mod P00002· FUNDING ONLY ACTION | 2016-08-30 | −$88,400 | $217,000 | BLANKET PO FOR FY16 FOR THE DRUG GLASSIA, ALPHA 1-PROTEINASE INHIBITOR HUMAN, 1GM/50ML VIAL 1200 VIALS. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI LT5GEHL2F1K6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25921F0372 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $26,600 | FY2021 |
| 36C26321N0774 | NETWORK CONTRACT OFFICE 23 (36C263) · 6505 · DRUGS AND BIOLOGICALS | $10,521 | FY2021 |
| 36C25921F0339 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $13,300 | FY2021 |
| 36C25921F0331 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $21,830 | FY2021 |
| 36C25921F0283 | NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS | $21,830 | FY2021 |
| 36C26121P0490 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $23,040 | FY2021 |
Other recipients under 6505 from 515-BATTLE CREEK(00515) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25018F0348 | SANOFI VACCINES US INC. | 515-BATTLE CREEK(00515) | $107,000 | FY2018 |
| 36C25018F0121 | PFIZER INC | 515-BATTLE CREEK(00515) | $14,554 | FY2018 |
| VA25017P3158 | AKAAL ORGANICS, LLC | 515-BATTLE CREEK(00515) | $16,200 | FY2017 |
| VA25017J2734 | TRAVERE THERAPEUTICS, INC. | 515-BATTLE CREEK(00515) | $27,468 | FY2017 |
| VA25017F2705 | CSL BEHRING L.L.C. | 515-BATTLE CREEK(00515) | $5,180 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA25116F0048_3600_V797P2140D_3600 · retrieved 2026-09-26.